HOME
ABOUT US
ADVERTISE
SUBSCRIBE
SITE MAP
HELP
CONTACT
WORK FOR US
Tuesday
7 September 2010
Make BTN my HomePage
GOVERNMENT BUSINESS STORIES
[ 321 Results - Showing Results 1 to 30 ]
In Silico: The verdict – a plague on both their houses
(Tuesday, 24 August 2010)
WHICHEVER way the chips fall in Canberra in the coming weeks, the outcome will certainly be a minority government. And the other certainty is that it will be a lean few years for life science companies hoping for a little more assistance from the federal government.
Full Story...
Innovators re-elected, Australia waits
(Sunday, 22 August 2010)
AS political leaders court Greens and independents to shore-up new coalitions, Innovation and Industry Minister Kim Carr and shadow minister Sophie Mirabella have been re-elected by voters.
Full Story...
FDA knocks back GBH fantasy
(Sunday, 22 August 2010)
A US Food and Drug Administration advisory panel has recommended a close formulation to controversial “date rape” drug gamma-hydroxybutyrate not be approved for a chronic fatigue indication after hearing there was a risk of widespread abuse.
Full Story...
Mirabella talks biotech, dollars
(Thursday, 19 August 2010)
FOLLOWING yesterday’s launch of the Liberal innovation policy,
BTN
asked Shadow Innovation Minister
Sophie Mirabella
to outline how her party’s policies would benefit the biotechnology industry. Here, Mirabella responds.
Full Story...
Libs abandon R&D tax credit to 'bring certainty'
(Thursday, 19 August 2010)
THE Coalition has released its innovation policy, promising to abandon the research and development tax credit and tip $11.4 million into the coffers of the Research Training Scheme.
BTN
spoke to industry and both sides of politics about potential effects on the life sciences.
Full Story...
Mesoblast progresses US orphan trial
(Tuesday, 17 August 2010)
BIOLOGIC products developer Mesoblast says it is on track to start an already-funded Phase 3 study of its off-the-shelf stem cells after a formal meeting with the US Food and Drug Administration.
Full Story...
Benitec-CSIRO wait on USPTO decision
(Thursday, 5 August 2010)
REPRESENTATIVES of RNAi developer Benitec and licensor CSIRO have attended a hearing of the US Patent and Trademark Office’s appeals board to re-examine the validity of a number of contested claims of the Graham patent for the control of gene expression – but have left without a decision.
Full Story...
OPINION: If we're not moving forwards, we're going backwards
(Thursday, 29 July 2010)
THE stalling of research and development tax credit legislation has forced companies into a holding pattern as they search for funding. The government should address this situation now, so the life science industry can pick itself up, brush itself off and get back to business, Licensing Executives Society of Australia & New Zealand president-elect
Mark Horsburgh
argues.
Full Story...
QRxPharma takes German lead
(Tuesday, 27 July 2010)
FOLLOWING a number of positive meetings with regulators in May, QRxPharma has selected Germany as its lead agency for European marketing authorisation application review, and will submit an application for its immediate release dual-opioid pain therapy next year.
Full Story...
Mesoblast gets TGA green light
(Thursday, 22 July 2010)
BIOLOGIC products developer Mesoblast expects to see first commercial sales of its proprietary mesenchymal precursor cells in Australia by the end of the year after receiving a Therapeutic Goods Administration licence to manufacture and supply the adult stem cells.
Full Story...
New funding to boost medical sector opportunities
(Tuesday, 20 July 2010)
THE $1 billion Parkville Comprehensive Cancer Centre in Melbourne is one project that will benefit from the $3.1 million in funding announced yesterday by the Australian Government to boost local companies’ chances of securing lucrative contracts around the world.
Full Story...
Hawaii assets sold
(Tuesday, 20 July 2010)
THE assets of Australia-listed Acuvax’s US investment Hawaii Biotech have been sold at auction to an unknown buyer.
Full Story...
Smaller unis get slice of funding pie
(Tuesday, 20 July 2010)
LESS research-intensive smaller and regional universities are being offered up to $51 million in federal government funds to strengthen their research capacity by partnering other institutions with similar interests.
Full Story...
In Silico: Don’t bet on the R&D tax bills anytime soon
(Tuesday, 20 July 2010)
PRIME Minister Julia Gillard’s decision to go to the polls on August 21 effectively puts an end to the chances of seeing the research and development tax credit changes introduced anytime soon. With the civil service and the government in caretaker mode and Parliament prorogued, the bills won’t be back for some time.
Full Story...
FDA lifts ChemGenex
(Thursday, 15 July 2010)
LATE-stage drug developer ChemGenex has recovered some lost ground, gaining up to 37% after the United States Food and Drug Administration invited it to file a new drug application for its chronic myeloid leukaemia treatment in patients who have failed therapy two or more times.
Full Story...
CA serves up $2.2M
(Thursday, 15 July 2010)
FUNDING body Commercialisation Australia has announced the projects to receive support from its second round of funding, with only two biotechnology projects receiving a total of $270,200 of the more than $2 million on offer.
Full Story...
Bio Briefs: Alchemia, Benitec, Stirling and more
(Thursday, 15 July 2010)
ALCHEMIA has more positive news for the market after last week’s rollercoaster, revealing it has entered into a marketing agreement with its partner Dr Reddy’s for its generic anticoagulant fondaparinux sodium in all markets outside of North America.
Full Story...
Mesoblast-Angioblast to connect with FDA
(Tuesday, 13 July 2010)
MESOBLAST group partner and takeover target Angioblast Systems has lined up a meeting with the US Food and Drug Administration for Phase 3 discussions later this month after a common complication of bone marrow transplants was dramatically reduced in the Texas trial of Mesoblast’s off-the-shelf stem cells.
Full Story...
Bio People: Starpharma, Avexa
(Tuesday, 13 July 2010)
NANOTECHNOLOGY developer Starpharma has selected long-time CSL employee Malcolm McColl its new vice-president of business development.
Full Story...
Alimera lodges NDA, pSivida gains
(Thursday, 1 July 2010)
PSIVIDA has gained 10% on the NASDAQ after licensee Alimera Sciences submitted a new drug application to the US Food and Drug Administration for Iluvien in diabetic macular edema patients.
Full Story...
Bio Briefs: R+D, Nanosonics, GTG and more *UPDATED*
(Tuesday, 29 June 2010)
FEDERAL Innovation and Industry Minister Kim Carr has told that if the government’s proposed research and development tax legislation is passed after July 1 it could still be implemented retrospectively.
Full Story...
In Silico: Doom and gloom round out the financial year
(Tuesday, 29 June 2010)
IT has been, by pretty much any standard, a pretty ordinary month on the market for the Australian life science sector. A combination of bad news for individual companies, poor sentiment in the broader markers and the odd external disaster here and there has made for a worse than usual end of financial year.
Full Story...
R&D tax credit legislation shelved
(Thursday, 24 June 2010)
AS Australia’s new prime minister settles in, the government has abandoned a July 1 implementation date for the proposed R&D tax credit after Opposition members “deliberately prolonged” other debate to ensure the R&D legislation would not pass the Senate.
Full Story...
OPINION: R&D legislation beneficial, but carries risk
(Thursday, 17 June 2010)
WHILE the government’s new tax credit legislation will benefit the biotechnology industry, the bill is likely to result in significantly more audits of small to medium-sized companies, BDO partner
Tracy Murray
predicts.
Full Story...
Bio People: MRCF, Acrux
(Thursday, 17 June 2010)
FORMER Queensland premier and long-time biotechnology champion Peter Beattie has been appointed a non-executive director of the Medical Research Commercialisation Fund.
Full Story...
R&D legislation clears Senate inquiry
(Thursday, 17 June 2010)
THE federal Parliament’s Senate inquiry into the new research and development tax credit has recommended the legislation be passed with some amendments by the end of June and is being debated in the House of Representatives today.
Full Story...
Sirtex awarded Gray payday
(Tuesday, 15 June 2010)
A Federal Court judge has ruled inventor and Sirtex Medical founder Dr Bruce Gray must pay the company he established 86% of its remaining legal costs – a payout estimated to be $A1.9 million.
Full Story...
Genes inquiry patently delayed
(Thursday, 10 June 2010)
ONGOING uncertainty over the patentability of genes has prompted the Senate Inquiry into Gene Patents to request another extension to its reporting date, this time until the end of the current session of Parliament in August.
Full Story...
ACCC pushes for uniform Vision Group clinic fees
(Thursday, 10 June 2010)
OPHTHALMIC care provider Vision Group may soon be able to allow employees and ophthalmologists engaged as contractors at its clinics to discuss and agree on patient fees if an Australian Competition and Consumer Commission authorisation proposal is accepted.
Full Story...
Bio Briefs: Benitec, Burnet, CRN and more
(Thursday, 3 June 2010)
BENITEC and CSIRO will present a united front at a United States Patent and Trademark Office appeals board hearing in August to argue that their Graham RNAi asset was invented six years before Nobel prize winner Dr Andrew Fire’s pioneering work.
Full Story...
Prev
Next
Company Search
Story Search
Advanced Search
UPCOMING
EVENTS
ABIC 2010 - Bridging Biology and Business
14th International Biotechnology Symposium & Exhibition 2010
BIO India Partnering Conference 2010
OZBIO2010
2010 Livestock Biotech Summit
BioPartnering Europe
View all events
TODAY'S NEWS
Broadvector prepares $24.5M bang
Bio People: Australia, Research Australia, KarmelSonix and more *UPDATED*
In Silico: Is the IPO window cracking open?
Capital Briefs: Select, Helicon, PharmaNet and more
Avexa-Calzada rebuffed or engaged?
Bio Briefs: Genesis, Epichem, Sirtex and more
HealthLinx breaches rule *UPDATED*
Pipeline Progress: QRxPharma, Tyrian, Prana and more
Market Pulse: Gaining amid uncertainty
Avexa bioadvisors on board
Disclaimer
|
© Copyright Aspermont Ltd
|
Privacy Policy
|
Terms and Conditions
R&D legislation clears Senate inquiry
